PRLD - Prelude Therapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PRLD is currently covered by 3 analysts with an average price target of $1.39. This is a potential upside of $0.5 (56.18%) from yesterday's end of day stock price of $0.89.

Prelude Therapeutics 's activity chart (see below) currently has 25 price targets and 32 ratings on display. The stock rating distribution of PRLD is 42.86% BUY, 50% HOLD and 7.14% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 32.86% with an average time for these price targets to be met of 65.2 days.

Highest price target for PRLD is $5, Lowest price target is $3, average price target is $4.

Most recent stock forecast was given by ROBERT BURNS from HC WAINWRIGHT on 08-Nov-2024.

Best performing analysts who are covering PRLD - Prelude Therapeutics :

Tazeen Ahmad Robert Burns Jeffrey Hung Peter Lawson Reni Benjamin

Currently out of the existing stock ratings of PRLD, 6 are a BUY (42.86%), 7 are a HOLD (50%), 1 are a SELL (7.14%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$5

$3.99 (395.05%)

$5

5 months 25 days ago
(08-Nov-2024)

5/14 (35.71%)

$3.8 (316.67%)

100

Hold

$3

$1.99 (197.03%)

$5

10 months 13 days ago
(20-Jun-2024)

2/5 (40%)

$-0.71 (-19.14%)

168

Sell

$4

$2.99 (296.04%)

$10

1 years 4 months 14 days ago
(19-Dec-2023)

2/7 (28.57%)

$-0.04 (-0.99%)

4

Hold

$6

$4.99 (494.06%)

$10

2 years 5 months 12 days ago
(21-Nov-2022)

3/5 (60%)

$-0.53 (-8.12%)

54

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PRLD (Prelude Therapeutics ) average time for price targets to be met?

On average it took 65.2 days on average for the stock forecasts to be realized with a an average price target met ratio 32.86

Which analyst has the current highest performing score on PRLD (Prelude Therapeutics ) with a proven track record?

TAZEEN AHMAD

Which analyst has the current lower performing score on PRLD (Prelude Therapeutics ) with a proven track record?

RENI BENJAMIN

Which analyst has the most public recommendations on PRLD (Prelude Therapeutics )?

Tazeen Ahmad works at BAML and has 16 price targets and 11 ratings on PRLD

Which analyst is the currently most bullish on PRLD (Prelude Therapeutics )?

Tazeen Ahmad with highest potential upside - $4.99

Which analyst is the currently most reserved on PRLD (Prelude Therapeutics )?

Reni Benjamin with lowest potential downside - -$0

Prelude Therapeutics  in the News

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025. On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?